Article

Kidney Cancer Vaccine Disappoints

The tumor-derived vaccine vitespen (Oncophage) does not prevent renal-cell carcinoma recurrence or improve survival despite promising early results.

The tumor-derived vaccine vitespen (Oncophage) does not prevent renal-cell carcinoma recurrence or improve survival despite promising early results.

Related Videos
Understanding Angioedema in Urticaria, with Jonathan Bernstein, MD
Brian Lee, MD | Credit: AASLD
Importance of Birch Triterpene Findings for Epidermolysis Bullosa, with Anna Bruckner, MD
Phase 3 Findings on Birch Triterpenes for Epidermolysis Bullosa, with Anna Bruckner, MD
Impact of Tapinarof Cream Approval for Atopic Dermatitis, with Adelaide Hebert, MD
Sobia Laique, MD | Credit: Cleveland Clinic
Sobia Laique, MD | Credit: Cleveland Clinic
What is the Global Lung Function Initiative and Its Purpose for Lung Function Testing?
Pranav Garimella, MBBS, MPH | Credit: GlobalNewsWire
© 2025 MJH Life Sciences

All rights reserved.